PHOTO
Pfizer Inc on Thursday reaffirmed the combined 2022 sales forecast of $54 billion for its COVID-19 vaccine and pill, as countries rushed to sign contracts to prepare for a surge of cases in the fall season.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
Reuters